IceCure Medical Ltd (ICCM)
Pre-market:
| Previous close | 1.2000 |
| Open | 1.1900 |
| Bid | 1.1800 x 400 |
| Ask | 1.2300 x 100 |
| Day's range | 1.1601 - 1.2000 |
| 52-week range | 0.5200 - 1.5700 |
| Volume | |
| Avg. volume | 491,519 |
| Market cap | 54.418M |
| Beta (5Y monthly) | 2.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.33 |
ZacksIceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
PR NewswireIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it has submitted final data to the U.S. Food and Drug Administration ("FDA") requesting marketing authorization for ProSense® for the indication of treating patients with early stage T1 invasive breast cancer with cryoablation and adjuvant hormone therapy
Insider MonkeyIceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript April 3, 2024 IceCure Medical Ltd isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and thank you for standing by. Currently, all participants are in a listen-only mode. After […]
